New Insights into the Mechanisms whereby Low Molecular Weight CCR5 Ligands Inhibit HIV-1 Infection*
暂无分享,去创建一个
Esther Kellenberger | E. Kellenberger | F. Arenzana‐Seisdedos | I. Staropoli | J. Alcamí | Fernando Arenzana-Seisdedos | J. García-Pérez | Bernard Lagane | Javier Garcia-Perez | Patricia Rueda | Isabelle Staropoli | Jose Alcami | B. Lagane | P. Rueda
[1] Bruno Antonny,et al. The apparent cooperativity of some GPCRs does not necessarily imply dimerization. , 2009, Trends in pharmacological sciences.
[2] S. Arya,et al. Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.
[3] Shoshana J. Wodak,et al. Activation of CCR5 by Chemokines Involves an Aromatic Cluster between Transmembrane Helices 2 and 3* , 2003, The Journal of Biological Chemistry.
[4] A. Christopoulos,et al. Kinetic studies of co-operativity at atrial muscarinic M2 receptors with an "infinite dilution" procedure. , 1997, Biochemical pharmacology.
[5] Thomas P. Sakmar,et al. Analysis of the Mechanism by Which the Small-Molecule CCR5 Antagonists SCH-351125 and SCH-350581 Inhibit Human Immunodeficiency Virus Type 1 Entry , 2003, Journal of Virology.
[6] R. Shattock,et al. C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors , 2010, The Journal of general virology.
[7] David A. Price,et al. Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity , 2005, Antimicrobial Agents and Chemotherapy.
[8] E. Freire,et al. Binding thermodynamics of the N-terminal peptide of the CCR5 coreceptor to HIV-1 envelope glycoprotein gp120. , 2009, Biochemistry.
[9] Yasushi Tojo,et al. Structural and Molecular Interactions of CCR5 Inhibitors with CCR5* , 2006, Journal of Biological Chemistry.
[10] Jun Zhang,et al. Molecular Interactions of CCR5 with Major Classes of Small-Molecule Anti-HIV CCR5 Antagonists , 2008, Molecular Pharmacology.
[11] A. Trkola,et al. Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140 , 2001, Journal of Virology.
[12] T. Kenakin,et al. The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry Inhibitor , 2005, Molecular Pharmacology.
[13] C. Broder,et al. Human immunodeficiency virus type-1 and chemokines: beyond competition for common cellular receptors. , 2001, Cytokine & growth factor reviews.
[14] M. Fidock,et al. Allosteric effects of antagonists on signalling by the chemokine receptor CCR5. , 2007, Biochemical pharmacology.
[15] H. Mitsuya,et al. Spirodiketopiperazine-Based CCR5 Inhibitor Which Preserves CC-Chemokine/CCR5 Interactions and Exerts Potent Activity against R5 Human Immunodeficiency Virus Type 1 In Vitro , 2004, Journal of Virology.
[16] T. Dragic,et al. An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry. , 2006, Virology.
[17] R. Ganju,et al. HIV-1 gp120-induced migration of dendritic cells is regulated by a novel kinase cascade involving Pyk2, p38 MAP kinase, and LSP1. , 2009, Blood.
[18] William C. Olson,et al. Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp120 Binding, and CC-Chemokine Activity by Monoclonal Antibodies to CCR5 , 1999, Journal of Virology.
[19] Peter D. Kwong,et al. Structures of the CCR5 N Terminus and of a Tyrosine-Sulfated Antibody with HIV-1 gp120 and CD4 , 2007, Science.
[20] P. Charneau,et al. Antibodies to several conformation-dependent epitopes of gp120/gp41 inhibit CCR-5-dependent cell-to-cell fusion mediated by the native envelope glycoprotein of a primary macrophage-tropic HIV-1 isolate. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[21] Serena Xu,et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[22] D. Cohen,et al. Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant P-glycoprotein with deleted phe(335). , 2000, Molecular pharmacology.
[23] H. Guy,et al. Epitope Mapping of CCR5 Reveals Multiple Conformational States and Distinct but Overlapping Structures Involved in Chemokine and Coreceptor Function* , 1999, The Journal of Biological Chemistry.
[24] John P. Moore,et al. Ternary Complex Formation of Human Immunodeficiency Virus Type 1 Env, CD4, and Chemokine Receptor Captured as an Intermediate of Membrane Fusion , 2005, Journal of Virology.
[25] T. Kenakin,et al. The Relative Activity of “Function Sparing” HIV-1 Entry Inhibitors on Viral Entry and CCR5 Internalization: Is Allosteric Functional Selectivity a Valuable Therapeutic Property? , 2009, Molecular Pharmacology.
[26] J. Alcamí,et al. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1 , 2007, Journal of medical virology.
[27] F. Galimi,et al. Two Mechanisms for Human Immunodeficiency Virus Type 1 Inhibition by N-Terminal Modifications of RANTES , 2003, Antimicrobial Agents and Chemotherapy.
[28] Sebastian Bonhoeffer,et al. The HIV coreceptor switch: a population dynamical perspective. , 2005, Trends in microbiology.
[29] David G Myszka,et al. Solubilization, stabilization, and purification of chemokine receptors using biosensor technology. , 2005, Analytical biochemistry.
[30] R. Doms,et al. Use of a gp120 Binding Assay To Dissect the Requirements and Kinetics of Human Immunodeficiency Virus Fusion Events , 1999, Journal of Virology.
[31] J. Sodroski,et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.
[32] M. Parmentier,et al. G Protein-Dependent CCR5 Signaling Is Not Required for Efficient Infection of Primary T Lymphocytes and Macrophages by R5 Human Immunodeficiency Virus Type 1 Isolates , 2003, Journal of Virology.
[33] M. Mack,et al. Aminooxypentane-RANTES Induces CCR5 Internalization but Inhibits Recycling: A Novel Inhibitory Mechanism of HIV Infectivity , 1998, The Journal of experimental medicine.
[34] G Vassart,et al. Multiple Charged and Aromatic Residues in CCR5 Amino-terminal Domain Are Involved in High Affinity Binding of Both Chemokines and HIV-1 Env Protein* , 1999, The Journal of Biological Chemistry.
[35] T. Kenakin. Functional Selectivity through Protean and Biased Agonism: Who Steers the Ship? , 2007, Molecular Pharmacology.
[36] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[37] A. Fauci,et al. Induction of phosphorylation and intracellular association of CC chemokine receptor 5 and focal adhesion kinase in primary human CD4+ T cells by macrophage-tropic HIV envelope. , 1999, Journal of immunology.
[38] Xavier Deupi,et al. The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex , 2009, Proceedings of the National Academy of Sciences.
[39] R. Doms,et al. Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. , 2009, Virology.
[40] C. Broder,et al. CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.
[41] D. Baker,et al. Realistic protein–protein association rates from a simple diffusional model neglecting long‐range interactions, free energy barriers, and landscape ruggedness , 2004, Protein science : a publication of the Protein Society.
[42] M. Parmentier,et al. Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the Protean Effects of “Selective” Antagonists* , 2009, The Journal of Biological Chemistry.
[43] J. Way,et al. Use of constitutive G protein-coupled receptor activity for drug discovery. , 2000, Molecular pharmacology.
[44] R. Lefkowitz,et al. β-Arrestins and Cell Signaling , 2007 .
[45] S. O. Smith,et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[46] M. Oppermann. Chemokine receptor CCR5: insights into structure, function, and regulation. , 2004, Cellular signalling.
[47] J. Howe,et al. Quantifying the relationship between HIV-1 susceptibility to CCR5 antagonists and virus affinity for antagonist-occupied co-receptor. , 2009, Virology.
[48] H. Mitsuya,et al. Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition. , 2008, Journal of molecular biology.
[49] M. Parmentier,et al. Genetics of resistance to HIV infection: Role of co-receptors and co-receptor ligands. , 2006, Seminars in immunology.
[50] John P. Moore,et al. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. , 2007, Virology.
[51] E. De Clercq,et al. HIV-1 gp120 and chemokine activation of Pyk2 and mitogen-activated protein kinases in primary macrophages mediated by calcium-dependent, pertussis toxin-insensitive chemokine receptor signaling. , 2001, Blood.
[52] C. Tremblay,et al. Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial. , 2010, The Journal of infectious diseases.
[53] G. Ciaramella,et al. Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry , 2006, Journal of Virology.
[54] Hana Golding,et al. Coreceptor Competition for Association with CD4 May Change the Susceptibility of Human Cells to Infection with T-Tropic and Macrophagetropic Isolates of Human Immunodeficiency Virus Type 1 , 2000, Journal of Virology.
[55] J. Mills,et al. Modified semliki forest virus expression vector that facilitates cloning. , 1997, BioTechniques.
[56] Q. Sattentau,et al. SDF-1/CXCL12 Production by Mature Dendritic Cells Inhibits the Propagation of X4-Tropic HIV-1 Isolates at the Dendritic Cell-T-Cell Infectious Synapse , 2010, Journal of Virology.
[57] P. Dorr,et al. Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. , 2005, Biochemical pharmacology.
[58] Shoshana J. Wodak,et al. The TXP Motif in the Second Transmembrane Helix of CCR5 , 2001, The Journal of Biological Chemistry.
[59] S. Rasmussen,et al. The structure and function of G-protein-coupled receptors , 2009, Nature.
[60] A. Heredia,et al. Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1 , 2008, Proceedings of the National Academy of Sciences.
[61] L. Vandekerckhove,et al. Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients. , 2009, The Journal of antimicrobial chemotherapy.
[62] Marc Parmentier,et al. Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. , 2002, Molecular biology of the cell.
[63] M. Hirsch,et al. Discovery and Characterization of Vicriviroc (SCH 417690), a CCR5 Antagonist with Potent Activity against Human Immunodeficiency Virus Type 1 , 2005, Antimicrobial Agents and Chemotherapy.
[64] M. Parmentier,et al. Mutation of the DRY Motif Reveals Different Structural Requirements for the CC Chemokine Receptor 5-Mediated Signaling and Receptor Endocytosis , 2005, Molecular Pharmacology.
[65] O. Nishimura,et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[66] R. Altmeyer,et al. Processing, Stability, and Receptor Binding Properties of Oligomeric Envelope Glycoprotein from a Primary HIV-1 Isolate* , 2000, The Journal of Biological Chemistry.
[67] N. Ray. Maraviroc in the treatment of HIV infection , 2008, Drug design, development and therapy.
[68] F. Dumas,et al. CD4 and CCR5 Constitutively Interact at the Plasma Membrane of Living Cells , 2006, Journal of Biological Chemistry.
[69] M. Parmentier,et al. Allosteric Modulation of Binding Properties between Units of Chemokine Receptor Homo- and Hetero-Oligomers , 2006, Molecular Pharmacology.